Problems in the evaluation of novel antipsychotic drugs;Zur problematik der beurteilung neuer antipsychotika

Wiener Medizinische Wochenschrift

Volumn 148, Issue 11-12, 1998, Pages 266-272

  Fleischhacker, W W ^a  

^a Univ Klinik für Psychiatrie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

ARTICLE; CLINICAL TRIAL; DRUG RECEPTOR BINDING; HUMAN; PATIENT SELECTION; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DRUG APPROVAL; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0031926440     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Alvir JMJ, Lieberman JA, Safferman, AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167.
2. Arato M, O'Connor R, Meltzer H, Bradbury J: Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia. European Neuropsychopharmacol 1997;7 (suppl 2): 214.
3. Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group: Multiple fixed doses of "Seroquel" (quetlapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiat 1997;42:233-246.
4. Barnas C, Stuppäck C, Unterweger B, Hinterhuber H, Fleischhacker WW: Treatment of negative symptoms in schizophrenia with zotepine. J Clin Psychopharmacol 1987;7:370.
5. Barnas C, Stuppäck C, Miller C, Haring C, Sperner-Unterweger B, Fleischhacker WW: Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms: a double blind trial vs. haloperidol. Int Clin Psychopharmacol 1992;7:23-27.
6. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, The Olanzapine HGAD Study Group: Olanzapine versus placebo and haloperidol. Neuropsychopharmacol 1996;14:111-123.
7. Borison RL, Arvanitis LA, Miller BG, Seroquel Study Group: ICI 204.636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-169.
8. Brook S, Swift R, Harrigan EP: The tolerability and efficacy of intramuscular ziprasidone. European Neuropsychopharmacol 1997;7 (suppl 2): 215.
9. Byerly MJ, DeVane CL: Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996;16:177-187.
10. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 1996;14 87-96.
11. Caligiuri MP, Lohr JB, Jeste DV: Parkinsonism in neurolepticnaive schizophrenic patients. Am J Psychiat 1993;150:1343-1348.
12. Casey DE: "Seroquel (quetiapine)": preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 1996;5:939-957.
13. Chatterjee A, Chakos M, Koreen AR, Geisler S, Sheitman B, Woerner M, Kane JM, Alvir JMJ, Lieberman MA: Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiat 1995;152:1724-1729.
14. Chouinard G, Albright PS: Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997;17:298-307.
15. Cooper SL, Butler A, Tweed J, Raniwalla J, Welch: Zotepine in the prevention of relapse. Poster presented at 6th World Congress of Biological Psychiatry, Nice, June 22-27, 1997.
16. Coukell A, Spencer M, Benfield P: Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1996;6:237-256.
17. Data on file, Eli Lilly and Company.
18. Data on file, Knoll Pharmaceuticals, Nottingham, UK.
19. Davis R, Markham A: Ziprasidone. CNS Drugs 1997;8:153-159.
20. Dieterle DM, Müller-Spahn F, Ackenheil M: Efficacy and tolerance of zotepine in a double-blind comparison with perazine in schizophrenics. Fortschr Neurol Psychiat 1991;18-22.
21. Dunn CJ, Fitton A: Sertindole. CNS Drugs 1996;5:224-230.
22. Emsley RA, McCreadie R, Livingston M, De Smedt G, Lemmens P: Risperidone in the treatment of first-episode patients with schizophreniform disorder. Poster presented at 8th ECNP Congress Venice. September 30 - October 4, 1995.
23. Fibiger HC: Neuroanatomical targets of neuroleptic drugs as revealed by Fos Immunochemistry. J Clin Psychiat 1994;55 (suppl B): 33-36 .
24. Flschman AJ, Bonab AA, Babich JW, Alpert NM, Rauch SL, Elmaleh DR, Shoup TM, Williams SA, Rubin RH: Positron emission tomographic analysis of central 5-hydroxtryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J Pharmacol Exp Ther 1996;279:939-947.
25. Fitton A, Heel R: Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990;40: 722-747.
26. Fleischhaoker WW, Lemmens P, Van Baelen B: A qualitative approach to assess neurological safety of antipsychotic drugs by analysing the risperidone integrated database. 1998;manuscript in preparation.
27. Fleischhacker WW, Barnas C, Stuppäck CH, Unterweger B, Miller CH, Hinterhuber H: Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull 1989; 25:97-100.
28. Fleischhacker WW, Link CGG, Horne B: A multicentre, double-blind, randomized comparison of dose and dose regimes of Seroquel™ in the treatment of patients with schizophrenia. Poster presented at the 34th ACNP Meeting. San Juan. December 11-15. 1995.
29. Fulton G, Goa KL: ICI-204,636. An initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs 1995;4:68-78.
30. Gardos G, Cole JO: The treatment of tardive dyskinesia. Psychopharmacology: The Fourth Generation of Progress. Raven Pressv 1995. Ed. Bloom F: 1503-1511.
31. Gefvert O, Lindstrom LH, Langstrom B, Bergstrom M, Lundberg T, Yates RA, Larsson SD, Tuersley MD: Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg Seroquel™ tid. Eur Neuropsychopharmacol 1995;5:347.
32. Geyer MA, Markou A: Animal models of psychiatric disorders. Psychopharmacology: The Fourth Generation of Progress, Raven Press. 1995; Ed. Bloom F; 787-798.
33. Goldstein JM: Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 1995; 4:291-298.
34. Goldstein J, Arvanitis L, Cantillon M: Low incidence of reproductive/hormonal side effects with seroquel (Quetiapine fumarate) is supported by its lack of elevation of plasma prolactin concentrations. Poster presented at the ninth biennial winter workshop on schizophrenia, Davos. Switzerland, February 7-13, 1998.
35. Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J: Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiat 1997;154:799-804.
36. Hale A, van der Burght M, Wehnert A, Friberg HH: A European dose-range study comparing the efficacy, tolerabillty and safety of four doses of sertindole and one dose of haloperidol in schizophrenic patients. Poster presented at the XXth CINP Congress. Melbourne. June 23-27, 1996.
37. Hamilton SH, Revicki DA, Genduso LA, Beasley jr. CM: Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacol 1998;18:41-49.
38. Hirsch S, Link CG, Goldstein JM, Arvanitis LA: ICI 20,636: a new atypical antipsychotic drug. Br J Psychiat 1996;168 (suppl 29): 45-56.
39. Hummer M, Kurz M, Barnas C, Saria A, Fleischhacker WW: Clozapine-induced transient white blood count disorders. J Clin Psychiat 1994;55:429-432.
40. Kanba S, Yagi G, Oguchi E, Nakaki T, Kato R, Richelson E: Neuropharmacology of zoteplne, an antimanic drug: a potent blokker of D2 and 5-HT2 receptors of human brain. Jpn J Psychiatr Neural 1991;45:133-134.
41. Kane J: What makes an antipsychotic atypical? Should the definition be preserved? CNS Drugs 1997;7:347-348.
42. Klieser E, Lehmann E, Tegeler J: Double-blind comparison of 3 × 75 mg zotepine and 3 × 4 mg haloperidol in acute schizophrenics. Fortschr Neurol Psychiat 1991;14-17.
43. Kraepelin E: Dementia praecox and paraphrenia. Edinburgh, Livingstone, 1919.
44. Kurz M, Hummer M, Oberbauer H, Fleischhacker WW: Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology 1995;118:52-56.
45. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stool JC, Janssen PA: Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661-670.
46. Lindström E, Eriksson B, Hellgren A, von Knorring L, Eberhard G: Efficacy and safety of risperidone in the longterm treatment of patients with schizophrenia. Clin Ther 1995;17:402-412.
47. Link C, Arvanitis L, Miller B, Fennimore J: A multicenter, double-blind, placebocontrolled, evaluation of Seroquel™ in hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia. Poster presented at the Vllth Congress of the European College of Neuropsychopharmacology, October 16-21, 1994, Jerusalem.
48. Mandoki MW: Risperidone treatment of children and adolescents: increased risk of extrapyramidal side effects? J Child Adolesc Psychopharmacol 1995;5:49-67.
49. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiat 1994;151:825-835.
50. Miller CH, Fleischhacker WW: Managing of antipsychotic induced acute and chronic akathisia. CNS Drugs (in press).
51. Möller HJ: The negative component in schizophrenia. Acta Psychiatr Scand 1995;91 (suppl 388): 11-14.
52. Petit M, Raniwalla J, Tweed J, Leutenegger E, Dollfus S, Kelly F: A comparison of an atypical and typical antipsychotic. zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double blind trial. Psychopharmacol Bull 1996;32:81-87.
53. Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, doubleblind, parallel-group study versus haloperidol. Br J Psychiat 1995;166:712-726.
54. Robertson GS, Fibiger C: Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology 1996; 14:105-110.
55. Skarsfeldt T: Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 1995;281:289-294.
56. Schultz SK, Miller DD, Arndt S, Ziebell S, Gupta S, Andreasen NC: Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation. Biol Psychiat 1995; 38:713-719.
57. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe III JA, Heym J: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275:101-113.
58. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG, Seroquel Study Group: Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiat 1997;54:549-557.
59. Sternlicht HC, Wells SR: Risperidone in childhood schizophrenia. J Am Acad Child Adolesc Psychiat 1995;34:5.
60. Stockton ME, Rasmussen K: Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacol 1996;14:97-104.
61. Tandon R, Harrigan E and Zorn SH: Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997;4:159-177.
62. Tollefson GD, Sanger TM, Beasley CM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiat 1997; 154:466-474.
63. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiat 1997;154:457-465.
64. Tran P, Dellva M, Tollefson G, Beasley jr. C, Potvin J, Kiesler G: Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiat 1997;58:205-211.
65. Tran P, Hamilton S, Kuntz A, Potvin J, Andersen S, Beasley C Jr, Tollefson G: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418.
66. Van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree T, Sertindole Study Group: A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996;124:168-175.
67. Waddington J, O'Callaghan E: What makes an antipsychotic 'atypical'? CNS Drugs 1997;7:341-346.
68. Weiß E, Danzl C, Hummer M, Kemmler G, Lindner C, Reinstadler K, Fleischhacker WW: Weight gain induced by olanzapine. Schizophrenia Res 1998;29 (special issue 1/2): 179.
69. Wetzel H, Bardeleben Uv, Holsboer F, Benkert O: Zotepine versus perazine in paranoid schizophrenia: a double-blind controlled trial of antipsychotic efficacy. Fortschr Neurol Psychiat 1991;23-29.
70. Wolfersdorf M, König F: Delusional depression: treatment with antidepressants and zotepine or haloperidol. Fortschr Neurol Psychiat 1993;61 (Sonderheft 1) :24.
71. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak TJ, Sebree TB, Wallin BA, Kashkin KB, Sertindole Study Group: Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiat 1997;154: 782-791.